image
Healthcare - Biotechnology - NASDAQ - US
$ 57.255
-2.42 %
$ 11.1 B
Market Cap
378.67
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INCY stock under the worst case scenario is HIDDEN Compared to the current market price of 57.3 USD, Incyte Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INCY stock under the base case scenario is HIDDEN Compared to the current market price of 57.3 USD, Incyte Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INCY stock under the best case scenario is HIDDEN Compared to the current market price of 57.3 USD, Incyte Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INCY

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
4.24 B REVENUE
14.76%
61.4 M OPERATING INCOME
-90.11%
32.6 M NET INCOME
-94.54%
335 M OPERATING CASH FLOW
-32.46%
158 M INVESTING CASH FLOW
175.85%
-2.02 B FINANCING CASH FLOW
-9991.08%
1.18 B REVENUE
3.59%
302 M OPERATING INCOME
106.40%
201 M NET INCOME
89.01%
381 M OPERATING CASH FLOW
22.63%
-21.5 M INVESTING CASH FLOW
-56.08%
20.4 M FINANCING CASH FLOW
163.04%
Balance Sheet Incyte Corporation
image
Current Assets 3.24 B
Cash & Short-Term Investments 2.16 B
Receivables 853 M
Other Current Assets 228 M
Non-Current Assets 2.21 B
Long-Term Investments 18.8 M
PP&E 794 M
Other Non-Current Assets 1.39 B
39.64 %15.67 %4.18 %14.59 %25.57 %Total Assets$5.4b
Current Liabilities 1.64 B
Accounts Payable 197 M
Short-Term Debt 4.42 M
Other Current Liabilities 1.44 B
Non-Current Liabilities 355 M
Long-Term Debt 33.5 M
Other Non-Current Liabilities 321 M
9.89 %72.12 %16.09 %Total Liabilities$2.0b
EFFICIENCY
Earnings Waterfall Incyte Corporation
image
Revenue 4.24 B
Cost Of Revenue 312 M
Gross Profit 3.93 B
Operating Expenses 3.87 B
Operating Income 61.4 M
Other Expenses 28.8 M
Net Income 32.6 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(312m)4b(4b)61m(29m)33mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.64% GROSS MARGIN
92.64%
1.45% OPERATING MARGIN
1.45%
0.77% NET MARGIN
0.77%
0.95% ROE
0.95%
0.60% ROA
0.60%
0.17% ROIC
0.17%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Incyte Corporation
image
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 32.6 M
Depreciation & Amortization 89.2 M
Capital Expenditures -86.3 M
Stock-Based Compensation 266 M
Change in Working Capital 0
Others 33 M
Free Cash Flow 249 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Incyte Corporation
image
Wall Street analysts predict an average 1-year price target for INCY of $85.6 , with forecasts ranging from a low of $48 to a high of $200 .
INCY Lowest Price Target Wall Street Target
48 USD -16.16%
INCY Average Price Target Wall Street Target
85.6 USD 49.58%
INCY Highest Price Target Wall Street Target
200 USD 249.31%
Price
Max Price Target
Min Price Target
Average Price Target
200200180180160160140140120120100100808060604040Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Incyte Corporation
image
Sold
0-3 MONTHS
2.42 M USD 2
3-6 MONTHS
1.74 M USD 4
6-9 MONTHS
1.29 M USD 3
9-12 MONTHS
2.88 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 week ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). businesswire.com - 3 weeks ago
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. globenewswire.com - 1 month ago
Why Incyte Stock Was Tanking This Week A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open. fool.com - 1 month ago
INCY Stock Down on Disappointing Skin Disease Study Data Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations. zacks.com - 1 month ago
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing. seekingalpha.com - 1 month ago
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial. investopedia.com - 1 month ago
Incyte Is Today's Worst S&P 500 Stock. Here's Why. The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough. barrons.com - 1 month ago
Incyte Stock Eyes Worst Day Since 2018 After Trial Results Incyte Corp  (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants. schaeffersresearch.com - 1 month ago
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). benzinga.com - 1 month ago
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. benzinga.com - 1 month ago
Incyte's skin disease drug meets main goal in two late-stage studies Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa. reuters.com - 1 month ago
8. Profile Summary

Incyte Corporation INCY

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 11.1 B
Dividend Yield 0.00%
Description Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Contact 1801 Augustine Cut-Off, Wilmington, DE, 19803 https://www.incyte.com
IPO Date Nov. 4, 1993
Employees 2617
Officers Ms. Christiana Stamoulis M.B.A. Executive Vice President & Chief Financial Officer Dr. Pablo J. Cagnoni M.D., Ph.D. President and Head of Research & Development Ms. Paula J. Swain Executive Vice President of Human Resources Mr. Thomas Tray Vice President of Finance, Chief Accounting Officer & Controller Mr. Michael James Morrissey Executive Vice President & Head of Global Technical Operations Dr. Steven H. Stein M.D. Executive Vice President & Chief Medical Officer Mr. Ben Strain Head of Investor Relations Ms. Sheila A. Denton J.D. Executive Vice President, General Counsel & Corporate Secretary Ms. Pamela M. Murphy Vice President of Investor Relations & Corporate Communications Mr. Herve Hoppenot Chairman, President & Chief Executive Officer